What We're Reading: Page 132
Industry reads hand-picked by our editors
Nov 30, 2021
-
Financial Times
The inside story of the Pfizer vaccine: 'a once-in-an-epoch windfall'
-
Evaluate Vantage
Biggest unpartnered assets: Argenx nears crunch time
-
The Washington Post
Pfizer poised to request authorization for coronavirus booster for 16 and 17 year olds
-
Endpoints News
FDA cancels ODAC meeting this week to review two more dangling accelerated approvals — but won’t explain why
Nov 29, 2021
-
Science
'Patience is crucial': Why we won't know for weeks how dangerous Omicron is
-
The Boston Globe
Alnylam getting a rare kind of leader
-
The Wall Street Journal
Drugmakers Gear Up for Price Restrictions in Biden's Legislative Agenda
-
Nature Biotechnology
The CRISPR children
Nov 24, 2021
Nov 23, 2021
-
Business Insider
Gene Editing Pioneer David Liu Developing Drug to Prevent Alzheimer's
-
Reuters
EQT, BioNTech investor consider bid for Novartis arm Sandoz - report
-
STAT
Sherif Zaki, a legendary disease detective at CDC, dies at 65
-
FierceBiotech
Founder-led biotech is making space for ideas—and diverse leaders—where it didn't exist before
Nov 22, 2021
-
C&EN
C&EN’s 2021 10 Start-Ups to Watch
-
STAT
FDA approves first drug for genetic cause of dwarfism
-
The Wall Street Journal
Novartis Rethinks Sales Strategy for New Cholesterol Drug Launch
-
The Washington Post
Treatments will change the pandemic, but they can’t end it alone
Nov 19, 2021
-
The Hill
CBO: Democrats' package saves about $160B on drug prices
-
Bloomberg
Insurers Balk at Paying for Biogen’s $56,000-a-Year Alzheimer’s Treatment
-
Chemical & Engineering News
Avilar Therapeutics launches with $60 million to degrade extracellular targets
-
Reuters
Wait what? FDA wants 55 years to process FOIA request over vaccine data
Nov 18, 2021
-
Bloomberg
Novartis Has a Big Pile of Cash and Investors Wanting Action
-
Reuters
J&J sees potential for 14 new multibillion-dollar drugs by 2025
-
FierceBiotech
Sanofi inks $270M cancer AI deal with R&D platform developer Owkin
-
The Wall Street Journal
Former Pittsburgh Steel Mill to Become Biomedical-Manufacturing Plant With Mellon Grant
Previous
